INTRODUCTION
Neo-vascular glaucoma (NVG) is a secondary glaucoma occurring with the formation of a fi brovascular membrane on the anterior surface of the iris (rubeosis iridis) which extends to the anterior chamber angle. presentation was 58.9 years and the age range was from 26 to 83 years. Patients aged 51 years and above were 22 (70.4%) as shown in Figure 1 .
The right eye alone was involved in 15 (48.0%) patients and the left eye alone in 13 (41.6%). Both eyes were involved in NVG in 3 (9.6%) patients. The presenting best corrected visual acuity (BCVA) in the aff ected eye, or in the be er eye where both eyes were aff ected, was counting fi ngers (CF) or worse in 30 (96%) patients. This is shown in Table 1 .
In the non-aff ected eye, 6 (19.4%) patients had visual acuity of 3/60 or worse. Twelve patients (38.7%) had no associated systemic disorders, while 10 patients (32%) and 1 patient (3.2%), respectively, had hypertension and diabetes mellitus (DM) only. However, seven (22.6%) patients had both hypertension and DM concurrently [ Table 2 ]. majority (78.7%) of subjects. [7] A study in Cameroon showed that NVG constituted 47.7% of all secondary glaucomas. [8] The most common causes of NVG in Romania are diabetic retinopathy, ischemic CRVO and ocular ischemic syndromes. [9] NVG accounted for 16 (22%) of all secondary glaucomas seen in a tertiary eye centre in Paraguay. [10] In Thailand, the most common causes of NVG were CRVO (47%), proliferative diabetic retinopathy (42%), and ocular ischemic syndromes (5%). [11] In Saudi Arabia, the common causes of neovascular glaucoma were diabetic retinopathy (56.0%), retina venous obstruction 26.4% and chronic retinal detachment (3.56%). [12] The treatment of NVG may be pharmacological or surgical such as trabeculectomy, aqueous drainage implants, cryotherapy or laser partial destruction of the ciliary body, photocoagulation of the hypoxic retina or a combination of any of these. The use of anti vascular endothelial growth factors is a signifi cant milestone in the management of NVG as they block the formation of new blood vessels in the eye. Bevacizumab, for example binds to the VEGF-A, thereby inhibiting angiogenesis. [13] The methods of treatment employed in a particular case can be individualized based on the available options, severity of disease and potential for vision.
This study aims to determine the common causes and outcome of treatment of NVG in patients a ending the retina clinic of the Lagos University Teaching Hospital.
MATERIALS AND METHODS
This is a retrospective study of the causes of and the outcome of treatment for NVG at the Guinness Eye Centre, Lagos University Teaching Hospital, Lagos, Nigeria. Ethical approval was obtained from the Lagos University Teaching Hospital Research and Ethics Commi ee. All new cases a ending the eye clinic from January 2008 to December 2012 with the diagnosis of 'NVG' had their records retrieved manually by the medical records offi cers. Information extracted from the records included bio-data, eye aff ected, best corrected visual acuity, intraocular pressure (IOP), etiology of NVG, ocular co-morbidity, systemic co-morbidity, and forms of treatment received. All cases of retinoblastoma were excluded as they are not normally labeled as cases of NVG in our centre. Data were analyzed using the SPSS V.17. 1
RESULTS
A total of 31 patients had NVG out of the total number of 52,335 new patients seen at the Guinness Eye Centre during the period of review. This gives a clinic incidence of 0.06%. There were 20 males and 11 females with a male to female ratio of 1.8:1. The mean age at Three (9.3%) patients had associated ocular trauma (couching). Ten (32%) patients had retinal vascular occlusion either without a known etiology or secondary to glaucoma or diabetic retinopathy [ Table 3 ].
Ocular medications alone (atropine, steroid eye drops and anti-glaucoma tablets and drops) represented the form of treatment most solely utilized by majority of the patients. Twenty-four (76.8%) patients took up this form of treatment alone, whereas, only 5 (16.0%) patients had a combination therapy consisting of ocular medications, intravitreal bevacizumab injections and pan-retina photocoagulation as shown in Table 4 .
The IOP at presentation was 30 mmHg or higher in 26 (83.2%) patients. In all, 15 (48.4%) patients failed to turn up for follow-up appointments after the fi rst visit. The remaining patients who turned up for appointments had varying IOP reductions depending on treatments received. Five (16%) patients who had a combination therapy of ocular medications, intraocular bevacizumab injections and retinal laser photocoagulation treatments showed an average IOP reduction of 19 mmHg [ Table 5 ]. However, the remaining 11 patients who came for follow-up but did not receive either intravitreal bevacizumab or PRP showed diff erent pa ern of IOP outcomes. While 3 eyes had a further elevation of IOP, one eye became phthisical [ Table 6 ].
DISCUSSION
With a male to female ratio of 1.8:1, male patients in this study were almost twice as many as females. This may be a refl ection of unequal access to eye care services rather than male susceptibility to NVG.
The mean age at presentation of 58.9 years is comparable to the mean age at presentation in the Ibadan study. [7] Twenty-two (70.4%) patients were aged 51 years and above with the age range 61-70 years having the highest frequency [ Figure 1 ]. This is to be expected as the diseases likely to cause NVG such as glaucoma, DM, and hypertension become more chronic with advancing age.
The BCVA at presentation was very poor. Thirty (96.8%) patients presented with BCVA of counting fi ngers or worse in the aff ected eye (or in the be er eye where both eyes were involved) suggesting that patients in this study generally presented late. This is underscored by the fi nding that no patients showed any improvement in vision and two of them actually deteriorated from BCVA of hand movement/perception of light to no perception of light. Systemic hypertension and DM, either alone or in combination, were the most important systemic disorders associated with NVG in this study. Both of these disorders may lead to retina ischemia and consequent neovascularization of the anterior segment of the eyes. Six (19.4%) patients were blind (cause of blindness not stated in the charts) in the contralateral eye at presentation and this underscores the importance of comprehensive eye examination for diabetic and hypertensive patients at regular patients. At the very least, each patient should have visual acuity and a direct fundoscopy at every clinic visit.
Couching was the etiology of NVG in three patients in this study as was the case in seven cases in the Ibadan study. [7] Couching, as a form of treatment for cataract, is still performed in Nigeria despite the availability of modern methods of cataract surgery. In the Nigerian National Blindness and Visual Impairment Survey, 46.1% of all operated cataracts was by couching. [14] The fi nding of couching as an etiology of NVG in this study suggests a persistent gap between availability of and accessibility to modern cataract surgery in Nigeria. In Lagos alone there are at least two tertiary eye centers, six secondary eye centers and numerous private ophthalmologists' clinics and yet patients still choose to patronize couching practitioners.
The majority of patients 24 (76.8%) received ocular medications alone as a form of treatment. This may be due to lack of funds to access other forms of treatment which are considerably more expensive. A dose of bevacizumab injection and a session of retina laser photocoagulation treatment, for example, may cost up to 35,000:00 naira (about 200 US dollars) each, a sum which is about twice the minimum wage in Nigeria. On the other hand it may be that patients did not wish to have any further treatments once the immediate concerns of pain have been alleviated by the initial ocular medications. Nonetheless, the result suggests a failure to deliver a particular form of eye care service to those who need it.
Most patients in this study presented with IOP of 30 mmHg or more, indicating a greater possibility of optic nerve damage and consequent loss of vision. The average IOP reduction of 19 mmHg occurred in fi ve patients who came for follow up and received a combination therapy of ocular medications (pressure lowering and anti-infl ammatory medications), intravitreal bevacizumab and pan-retina laser photocoagulation. This suggests that a combination therapy may reduce IOP and, perhaps, preserve vision in NVG if the patient presents early. None of the patients in this study received such forms of treatment as valve drainage implants or cyclo-destruction by laser or cryo-therapy. This represents a limitation of the options of treatment for NVG in our center but their impact on outcome of treatment in our environment needs to be studied as most of the patients presented rather late.
CONCLUSION
Late presentation, loss to follow up and lack of full and complete treatment regime were important fi ndings in this study. A routine eye examination for patients at risk is essential for early detection and prompt treatment for be er visual outcome. Such patients should at least include all diabetics and hypertensives.
